# Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

> **NCT04267640** · PHASE2 · UNKNOWN · sponsor: **AnGes USA, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Peripheral Artery Disease
- Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease
- Chronic Limb Threatening Ischemia
- Ischemic Ulcer of Foot

## Interventions

- **BIOLOGICAL:** AMG0001
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04267640
- **Lead sponsor:** AnGes USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-30
- **Primary completion:** 2022-07
- **Final completion:** 2023-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267640, "Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04267640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*